Life Sciences Virtual Investor Forum Agenda Announced

Life Sciences Virtual Investor Forum Agenda Announced

Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Forum taking place on September 17, 2026.

REGISTER HERE

Individual investors, institutional investors, advisors, and analysts are invited to attend.

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to attend live presentations or schedule one-on-one meetings with company management.

Schedule 1x1 meetings here.

"We're looking forward to bringing together innovators from the life sciences sector for this Virtual Investor Forum," said Greg Young, VP, Corporate Services, OTC Markets Group. "The event gives these clinical-stage and commercial companies an efficient platform to share pipeline updates and engage directly with a global investor audience."

September 17th

Presentation Time (ET) Company Tickers
10:30 AM ET Avicanna Inc. OTCQX: AVCNF | TSX: AVCN 
11:00 AM ET Sona Nanotech Inc. OTCQB: SNANF | CSE: SONA,OTC:SNANF
11:30 AM ET Raphael Pharmaceutical Inc. OTCQB: RAPH
1:00 PM ET Adaptin Bio, Inc. OTCQB: APTN
2:00 PM ET Amplia Therapeutics Ltd. OTCQB: INNMF | ASX: ATX
2:30 PM ET Altrova Health Inc. OTCQB: ATVHF | CSE: ROVA
3:30 PM ET CytoDyn Inc. OTCQB: CYDY
4:00 PM ET 4DMedical Ltd. OTC: FDMDF | ASX: 4DX


To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

About Virtual Investor Conferences®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

Media Contact: 
OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com

Virtual Investor Conferences Contact:
Greg Young

VP Corporate Services

OTC Markets Group

(212) 652-5958

greg@otcmarkets.com 


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

SONA:CC
The Conversation (0)
Sona Nanotech

Sona Nanotech

Advancing breakthrough cancer therapy through nanotechnology

Advancing breakthrough cancer therapy through nanotechnology Keep Reading...
Longeveron Granted Small or Medium-sized Enterprise  Status by the European Medicines Agency

Longeveron Granted Small or Medium-sized Enterprise Status by the European Medicines Agency

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has been granted Small or Medium-sized Enterprise (SME) status by the European Medicines... Keep Reading...
Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Longeveron® Announces Contract Development and Manufacturing Business and First Contract

Contract manufacturing services as a new business line has the potential to generate approximately $4-5 million in annual revenues First manufacturing services contract signed with Secretome Therapeutics Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company... Keep Reading...
Immatics Announces First Quarter 2024 Financial Results and Business Update

Immatics Announces First Quarter 2024 Financial Results and Business Update

Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME Updated clinical data on ACTengine® IMA203 targeting PRAME in 30 heavily pre-treated metastatic melanoma patients at RP2D: 55% confirmed objective response rate, including tumor... Keep Reading...
Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona's 'THT' Cancer Therapy to be Assessed for Efficacy and Ability to Act as a Catalyst to Generate Immune Responses in Research Study

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce an innovative research initiative to be undertaken with The Giacomantonio Immuno-Oncology Research Group (the "Research Group"). This study aims to evaluate the efficacy of Sona's Targeted... Keep Reading...
Why Invest in Nanotech Stocks?

Why Invest in Nanotech Stocks?

The nanotechnology market is experiencing a promising stage of growth, making it an attractive space for investors.From nanotech-based solar panels that increase energy efficiency to pharmaceutical products that make use of nanotech in drug-delivery systems, nanotechnology has far-reaching... Keep Reading...

SILO Pharma Inc

SILO Pharma Inc is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. Keep Reading...

Interactive Chart

Latest Press Releases

Related News